As mentioned above, DPP-4 inhibitors are now an established and successful class of oral anti-hyperglycaemic agents, and are firmly embedded in guidelines for treating T2DM patients without atherosclerotic cardiovascular (CV) disease (116, 117). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.